A London-based Iranian neurosurgeon who is leading the first ever brain cancer vaccine trial in Europe, says he is satisfied with the initial results of this new therapy for the most aggressive form of brain cancer known as “glioblastomatumour”.
Iranian surgeon: brain cancer vaccine is a promising therapy
In an exclusive interview with IRNA, Dr Keyoumars Ashkan, consultant neurosurgeon and Reader (Associate Professor) at King’s College Hospital London, said this is an individualised treatment based on each patientˈs own cancer type because glioblastomas are genetically different.
Under the supervision of Dr Ashkan, the first patient in Europe, a 62 year old male, has received the new vaccine in September last year. The vaccine had been produced from his own tumour after an operation in June.
“Since September we have recruited another 10 patients at Kingˈs College Hospital to this trial and so far I am happy with the progress of the trial ”, said DrAshkan, who is also the Lead for Neuro-Oncology at King’s College as well as a fellow of the Royal College of Surgeons in Neurosurgery.
However he stressed that this is still a trial and “we should be patient and test the vaccine on more patients to see how effective it would be at the end of the trial process.”
Source: irna.ir
B.N